Cerevast Therapeutics, Inc. is a medical technology company with primary emphasis in the field of SonoLysis for the treatment acute ischemic stroke and other vascular disorders. This non-invasive treatment is administered with Cerevast’s proprietary ultrasonic headframe called the ClotBust-ERTM, an operator independent device that can be rapidly and easily deployed by virtually any emergency room staff to safely administer the ultrasound energy for SonoLysis therapy.

Cerevast was formed in September of 2009 following the acquisition of substantially all of the assets of ImaRx Therapeutics, Inc. – a publicly traded company focused on the development of microsphere contrast agents and therapeutics. Through this acquisition, Cerevast gained title to the dominant intellectual property estate and an extensive data package of pre-clinical and clinical studies.

Cerevast has assembled a management team with extensive technical, scientific, commercial and regulatory expertise. The company has also assembled a Scientific Advisory Board comprised of globally recognized clinicians, all of whom are leading experts in the field of SonoLysis, ultrasound development and stroke treatment.

The company’s headquarters are located in Redmond, Washington.

Show more
Type
Private
HQ
Redmond, US
Founded
2015
Size (employees)
15 (est)+16%
Cerevast Therapeutics was founded in 2015 and is headquartered in Redmond, US
Report incorrect company information

Key People/Management at Cerevast Therapeutics

Bradford Zakes

Bradford Zakes

President & Chief Executive Officer
Mark Moehring

Mark Moehring

Chief Technology Officer
Anthony Alleman

Anthony Alleman

Chief Operating Officer
W.j. Tyler

W.j. Tyler

Chief Scientific Officer
Mike Rothmeyer

Mike Rothmeyer

Senior Vice-President, Global Sales and Marketing
Andrew Leo

Andrew Leo

Vice President of Quality and Regulatory Affairs

Cerevast Therapeutics Office Locations

Cerevast Therapeutics has an office in Redmond
Redmond, US (HQ)
100 11601 Willows Rd
Show all (1)
Report incorrect company information

Cerevast Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2015

Total Funding

$22.4 m

Latest funding size

$11.40 m

Time since last funding

3 years ago

Investors

Cerevast Therapeutics's latest funding round in March 2015 was reported to be $11.4 m. In total, Cerevast Therapeutics has raised $22.4 m
Show all financial metrics
Report incorrect company information